-
GRUNENTHAL GMBH et al v. ACTAVIS ELIZABETH LLC et al DC CAFC
- 2:13-cv-04507
- D.N.J.
- Judge: Claire C. Cecchi +1
- Filed: 07/25/2013
- Closed: 04/11/2017
- Latest Docket Entry: 03/15/2022
- PACER
- Docket updated daily
3
Plaintiffs
6
Defendants
3
Accused
Products
3
Patents-in-Suit
1,357
Days in
Litigation
-
GRUNENTHAL GMBH et al v. ACTAVIS ELIZABETH LLC et al DC CAFC
- 2:13-cv-04507
- D.N.J.
- Judge: Claire C. Cecchi +1
- Filed: 07/25/2013
- Closed: 04/11/2017
- Latest Docket Entry: 03/15/2022
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K<sub>α</sub> radiation at 15.1±0.2, 16.0±0.2,
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
2 |
The crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting at least X-ray lines (2-theta values) in a powder diffraction when measured using Cu K<sub>α</sub> radiation at
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
3 |
The crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride according to claim 1 exhibiting an X-ray pattern (2-theta values) in a powder diffraction when measured using Cu K<sub>α</sub> radiation essentially
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
25 |
A solid pharmaceutical composition comprising, as an active ingredient, a crystalline Form A of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride exhibiting at least X-ray lines (2-theta values) in a powder diffraction
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
Claim # | Claim Text | Outcome |
---|---|---|
8 |
A method of treating a mammal suffering from pain, said method comprising administering to said mammal an effective analgesic amount of a 1-phenyl-3-dimethylaminopropane compound corresponding to formula I<chemistry id="CHEM-US-00044"
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
61 |
<?insert-start id="INS-S-00062" date="20070424" ?>61. (−)-(<i>1R,2R</i>)-<i>3</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol hydrochloride </i>(−<i>21</i>).<?insert-end id="INS-S-00062" ?>
|
Enforceable and Valid
Entry 582 Entry 616 |
117 |
<?insert-start id="INS-S-00118" date="20070424" ?>117. A method according to claim 8, wherein the compound is (−)-(<i>1R,2R</i>)-<i>3</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol hydrochloride
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
147 |
<?insert-start id="INS-S-00148" date="20070424" ?>147. A pharmaceutically acceptable salt of (−)-(<i>1R,2R</i>)-<i>3R</i>-(<i>3</i>-<i>dimethylamino</i>-<i>1</i>-<i>ethyl</i>-<i>2</i>-<i>methylpropyl</i>)-<i>phenol.<?insert-end id="INS-S-00148"
view more
|
Enforceable and Valid
Entry 582 Entry 616 |
-
Infringement
Actavis Elizabeth LLC
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tabletsGeneric 50 mg, 75 mg, 100 mg tapentadol hydrochloride tablets | US 7,994,364 B2 |
1, 2, 3, 25
|
Infringement
Entry 616Entry 582 |
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tabletsGeneric 50 mg, 75 mg, 100 mg tapentadol hydrochloride tablets | US RE39,593 E1 |
8, 61, 117, 147
|
Infringement
Entry 616Entry 582 |
Actavis Ut
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tablets | US 7,994,364 B2 |
1, 2, 3, 25
|
Infringement
Entry 616
|
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tablets | US RE39,593 E1 |
8, 61, 117, 147
|
Infringement
Entry 616
|
Alkem Laboratories Limited
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tabletsGeneric 50 mg, 75 mg, 100 mg tapentadol hydrochloride tablets | US 7,994,364 B2 |
1, 2, 3, 25
|
Infringement
Entry 616Entry 582 |
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tabletsGeneric 50 mg, 75 mg, 100 mg tapentadol hydrochloride tablets | US RE39,593 E1 |
8, 61, 117, 147
|
Infringement
Entry 616Entry 582 |
Roxane Laboratories Incorporated
- 2 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tablets | US 7,994,364 B2 |
1, 2, 3, 25
|
Infringement
Entry 616
|
100 mg, 200 mg, 250 mg generic tapentadol hydrochloride extended release tablets 50 mg, 100 mg, 150 mg, 200 mg, 250 mg tapentadol hydrochloride extended release tablets 50 mg, 75 mg, 100 mg generic tapentadol hydrochloride tablets | US RE39,593 E1 |
8, 61, 117, 147
|
Infringement
Entry 616
|